Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer.

Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P.

Br J Cancer. 2014 Mar 4;110(5):1236-43. doi: 10.1038/bjc.2014.11. Epub 2014 Jan 28.

2.

Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD.

Kratzer A, Chu HW, Salys J, Moumen Z, Leberl M, Bowler R, Cool C, Zamora M, Taraseviciene-Stewart L.

J Pathol. 2013 Aug;230(4):388-98. doi: 10.1002/path.4197.

PMID:
23649916
3.

Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome.

Najjar F, Alammar M, Bachour M, Al-Massarani G.

Int J Biol Markers. 2014 Dec 9;29(4):e337-44. doi: 10.5301/jbm.5000100.

PMID:
25041783
4.

Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.

Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N.

Eur J Cardiothorac Surg. 2007 Sep;32(3):435-9. Epub 2007 Jul 3.

PMID:
17611117
5.

Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.

Yuan DM, Zhang Q, Lv YL, Ma XQ, Zhang Y, Liu HB, Song Y.

Tumour Biol. 2015 Nov;36(11):9031-7. doi: 10.1007/s13277-015-3657-y. Epub 2015 Jun 18.

PMID:
26084612
6.

Baseline and post-surgery endothelial progenitor cell levels in patients with early-stage non-small-cell lung carcinoma: impact on cancer recurrence and survival.

Pirro M, Cagini L, Paciullo F, Pecoriello R, Mannarino MR, Bagaglia F, Capozzi R, Puma F, Mannarino E.

Eur J Cardiothorac Surg. 2013 Oct;44(4):e245-52. doi: 10.1093/ejcts/ezt382. Epub 2013 Jul 23.

PMID:
23882070
7.

Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer.

Najjar F, Alammar M, Al-Massarani G, Almalla N, Aljapawe A, Ikhtiar A.

Cancer Biomark. 2017 Sep 7;20(3):333-343. doi: 10.3233/CBM-170130.

PMID:
28800312
8.

Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.

Hu Y, Hu MM, Shi GL, Han Y, Li BL.

Eur J Surg Oncol. 2014 Sep;40(9):1136-42. doi: 10.1016/j.ejso.2014.05.014. Epub 2014 Jun 26.

9.

Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.

Suzuki H, Ishikawa S, Satoh H, Ishikawa H, Sakai M, Yamamoto T, Onizuka M, Sakakibara Y.

Eur J Cardiothorac Surg. 2007 Oct;32(4):648-52. Epub 2007 Aug 17.

PMID:
17707649
10.

[Circulating endothelial cells in the peripheral blood of advanced NSCLC patients].

Huang C, Li K, Wei XY, Niu RF, Sun Y, Wang JW, Zhu YZ, Xu LY, Liu XQ, Gao HJ, Zhou JM, Wang XW.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):780-3. Chinese.

PMID:
17366796
11.

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ.

Br J Cancer. 2012 Mar 13;106(6):1153-9. doi: 10.1038/bjc.2012.50. Epub 2012 Feb 21.

12.

Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.

Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Yamada S, Tanaka F.

Clin Lung Cancer. 2013 May;14(3):288-94. doi: 10.1016/j.cllc.2012.09.005. Epub 2012 Nov 1.

PMID:
23122494
13.

Circulating endothelial cells in coronary artery disease.

Lampka M, Grąbczewska Z, Jendryczka-Maćkiewicz E, Hołyńska-Iwan I, Sukiennik A, Kubica J, Halota W, Tyrakowski T.

Kardiol Pol. 2010 Oct;68(10):1100-5.

14.

Hematogenous dissemination of lung cancer cells during surgery: quantitative detection by flow cytometry and prognostic significance.

Dong Q, Huang J, Zhou Y, Li L, Bao G, Feng J, Sha H.

Lung Cancer. 2002 Sep;37(3):293-301.

PMID:
12234699
15.

[Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].

Shen L, Li ZM, Lu S.

Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):442-6. Chinese.

PMID:
21875485
16.

Circulating endothelial cells and tumor blood volume as predictors in lung cancer.

Wang J, Xiao J, Wei X, Wang L, Lin L, Liu Z, Wang X, Sun B, Li K.

Cancer Sci. 2013 Apr;104(4):445-52. doi: 10.1111/cas.12097. Epub 2013 Feb 9.

17.
18.

Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer.

Wang CY, Huang MS, Huang MH, Lee HC, Hsu HS.

J Surg Res. 2010 Oct;163(2):e45-50. doi: 10.1016/j.jss.2010.04.039. Epub 2010 May 21.

PMID:
20638687
20.

High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.

Taylor M, Rössler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, Farace F.

Clin Cancer Res. 2009 Jul 15;15(14):4561-71. doi: 10.1158/1078-0432.CCR-08-2363.

Supplemental Content

Support Center